ストックスクリーナーアプリを入手
28.09
4.85%
1.30
アフターアワーズ：
28.00
-0.09
-0.32%
Castle Biosciences Inc (CSTL) 最新ニュース
Castle Biosciences Inc (CSTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Castle Biosciences Inc (CSTL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Castle Biosciences Inc (CSTL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Castle Biosciences Inc (CSTL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Castle Biosciences Inc (CSTL) Cash Flow - TradingKey
Earnings Preview: CSTL to Report Financial Results Post-market on July 30 - Moomoo
Castle Biosciences Inc (CSTL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Castle Biosciences, Inc. (CSTL) Investor Outlook: Exploring A 67.89% Potential Upside - DirectorsTalk Interviews
CSTL|Castle Biosciences Inc|Price:25.093|Chg%:-0.387 - TradingKey
Castle Biosciences sets live webcast for Aug. 12 conference - Stock Titan
New York State Department of Health Approves Castle’s AdvanceAD-Tx Test - The Dermatology Digest
The Technical Signals Behind (CSTL) That Institutions Follow - Stock Traders Daily
Castle Biosciences CEO Maetzold sells $95,622 in company stock - Investing.com UK
Form 4 Castle Biosciences Inc For: 16 July By Investing.com - Investing.com Nigeria
Castle Biosciences CEO Maetzold sells $95,622 in company stock By Investing.com - Investing.com UK
Castle Biosciences (CSTL) CEO sells 4,172 shares via family trusts - Stock Titan
Castle Biosciences CEO Derek J. Maetzold disposes of 550 common shares worth $12,606 - Bitget
Castle Biosciences Gets New York State Department of Health Approval of AdvanceAD-Tx Test - Moomoo
Castle Biosciences receives New York approval for atopic dermatitis test By Investing.com - Investing.com Nigeria
Castle Biosciences receives New York approval for atopic dermatitis test - Investing.com
Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test - norfolkneradio.com
CSTL Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline Amid Uncertain Revenue Outlook - DonanımHaber
Castle Biosciences Inc (CSTL) Stock Down 3.4% -- Now Undervalued? GF Score: 77/100 - GuruFocus
CSTL Q1 2026 Earnings: Slight EPS Beat Amid Operational ProgressRevenue Guidance Update - DonanımHaber
July 30 set for Castle Biosciences Q2 2026 earnings webcast - Traders Union
Castle Biosciences (CSTL) to Release Q2 Financial Results on Jul - GuruFocus
Castle Biosciences sets July 30 webcast for Q2 results - Stock Titan
Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026 - Yahoo Finance
Castle Biosciences updates its melanoma testing strategy as diagnostics demand grows - Ad-hoc-news.de
Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus - AOL.com
Castle Biosciences (CSTL) COO sells 8,586 shares under 10b5-1 plan - Stock Titan
Form 4 Castle Biosciences Inc For: 6 July By Investing.com - Investing.com Nigeria
Derek Maetzold, pres. & CEO, sells $238,916 of Castle Biosciences stock - Investing.com India
Castle Biosciences (CSTL) CEO sells 9,836 shares via 10b5-1 plan - Stock Titan
Q1 2026 Castle Biosciences Inc Earnings Call Transcript - GuruFocus
Enterprise value to revenue forward of Castle Biosciences, Inc. – NASDAQ:CSTL - TradingView
Castle Biosciences Inc (CSTL) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Form 144 Castle Biosciences For: 1 July By Investing.com - Investing.com Canada
Maetzold family Rule 144 sales reported for CSTL (CSTL) — multiple small lots - Stock Titan
Castle Biosciences (CSTL) Surges 6% as Bullish Momentum BuildsDynamic Hedging - dars.gov.et
Castle Biosciences updates its melanoma test data, shares in biotech focus - AD HOC NEWS
Castle Biosciences (CSTL) Stock Sees Split Analyst Revisions As Price Targets Come Down - Yahoo Finance
Castle Biosciences (CSTL) Study Highlights Advancements in Melan - GuruFocus
Castle Biosciences, Inc. Actuals & Estimates (NASDAQ:CSTL) - TradingView
Castle Biosciences’ melanoma test outperforms risk tool By Investing.com - Investing.com South Africa
Castle Biosciences, Inc. Actuals & Estimates (TRADEGATE:086) - TradingView
Castle Biosciences’ melanoma test outperforms risk tool - Investing.com
Enterprise value to EBIT forward of Castle Biosciences, Inc. – NASDAQ:CSTL - TradingView
DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy - norfolkneradio.com
Roth Capital Initiates Castle Biosciences at Buy - Moomoo
Precision Trading with Castle Biosciences Inc. (CSTL) Risk Zones - Stock Traders Daily
CSTL Forecast — Price Target — Prediction for 2027 - TradingView
CSTL Initiated by Roth Capital -- Price Target Announced at $40. - GuruFocus
Price to earnings forward of Castle Biosciences, Inc. – NASDAQ:CSTL - TradingView
Enterprise value to EBITDA forward of Castle Biosciences, Inc. – NASDAQ:CSTL - TradingView
Enterprise value to revenue forward of Castle Biosciences, Inc. – TRADEGATE:086 - TradingView
Castle Biosciences (CSTL) Receives Buy Rating and $40 Target fro - GuruFocus
0.55%
2.63%
大文字化:
|
ボリューム (24 時間):